Effects of pimobendan (UDCG 115) on renal function in healthy volunteers.
A phase I, double-blind, single-dose, randomized, two-period crossover study was conducted to investigate the effects of pimobendan on renal function to assess whether renal events were a contra-indication to its administration. Results in eight healthy volunteers indicated no significant adverse events on renal plasma flow, glomerular filtration rate, or laboratory safety screens; side-effects were also found to be minimal. Further studies are indicated to assess whether, in the proposed treatment group, i.e. patients with heart failure (in whom compromised renal function is common), pimobendan similarly elicits no serious adverse renal effects.
Martin
P
P
University Department of Medicine, General Infirmary, Leeds, UK.
Tindall
H
H
Rice
P
P
Jones
P
P
Tregunno
G
G
Davies
J A
JA
Prentice
C R
CR
D000328:Adult; D002316:Cardiotonic Agents / Q000633:toxicity*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D008297:Male; D011724:Pyridazines / Q000633:toxicity*; D012016:Reference Values; D012079:Renal Circulation / Q000187:drug effects*
D002316:Cardiotonic Agents; D011724:Pyridazines; C041648:pimobendan